|
September 30, 2026
|
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
|
|
|
September 15, 2026
|
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
|
|
|
September 3, 2026
|
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
|
|
|
August 12, 2026
|
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
|
|
|
June 17, 2026
|
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
|
|
|
May 12, 2026
|
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
|
|
|
May 12, 2026
|
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
|
|
|
April 23, 2026
|
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
|
|
|
March 31, 2026
|
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
|
|
|
March 30, 2026
|
Connect Biopharma Announces $20.2 Million Private Placement Financing
|
|
